Amgen Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Hello, everyone, and welcome to Oppenheimer's 31st Annual Healthcare Conference. I'm Jay Olson, one of the biotech analysts at Oppenheimer. And I want to thank you all for joining us. It's my pleasure to welcome Amgen to our conference and it's an honor to introduce Arvind Sood, Head of Investor Relations; Rob Lenz, Head of Global Development; and David Reese, Head of R&D.
We're really excited about all the progress at Amgen, and appreciate the opportunity to catch up with you today. So thank you for participating in our conference.
And with that, I'll turn it over to you, Arvind.
Great. Thank you, Jay. Good morning, good afternoon, everybody. Hey, Jay, thank you for inviting us to your conference. I will briefly touch on some broad issues, and we can then jump into some specific R&D topics with Dave and Rob. So I've been thinking, Jay, about the one question you had raised previously, which is what
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
